Under the terms of the agreement, Novartis remains the holder of the registration of these medicines and will be responsible to manufacture them, Glenmark will be responsible for promoting, commercializing and distributing of these products in Brazil.from Moneycontrol Business News http://bit.ly/2NnbFLt
No comments:
Post a Comment